United States News All stories

General Mills (NYSE:GIS) reported first-quarter fiscal 2027 net sales of $4.4 billion, down 3% from the prior year due mainly to the impact of the U.S. yogurt business divestiture.

Manchester United (NYSE:MANU) reported record fiscal 2026 revenue of £677.6 million for the year ended June 30, 2026, while returning to operating profit.

ANI Pharmaceuticals (NASDAQ:ANIP) received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension.

RPM International (NYSE:RPM) signed a definitive agreement to acquire Volteco S.p.A., an Italy-based supplier of below-grade waterproofing solutions, for its Tremco Construction Products Group.

Surf Air Mobility (NYSE:SRFM) signed a definitive agreement with SkyDance Air for OperatorOS, its SurfOS flight operations software platform powered by Palantir Technologies (NASDAQ:PLTR).

AEVEX Corp. (NYSE:AVEX) announced Specter, a jet-powered autonomous platform under development using modular design and scalable manufacturing methods.

Target Corporation (NYSE:TGT) declared a regular quarterly dividend of $1.16 per common share, payable on December 1, 2026.

Meta Platforms (NASDAQ:META) is expected to unveil new smart glasses at its annual Connect conference, including a camera-free model amid growing privacy concerns.

NW Natural Holding Company (NYSE:NWN) said its SiEnergy subsidiaries reached a settlement with key parties in a Texas general rate case that includes an $8.6 million annual revenue increase.

Cardiol Therapeutics (NASDAQ:CRDL) reached its original enrollment target for the Phase III MAVERIC trial of CardiolRx in recurrent pericarditis and plans to expand enrollment to up to 150 patients.

Kimberly-Clark (NYSE:KMB) offered concessions to address European Union antitrust concerns regarding its proposed $40 billion acquisition of Kenvue (NYSE:KVUE), according to a European Commission filing.

The UK Competition and Markets Authority proposed new rules that would require Google (NASDAQ:GOOGL) to give Android and Chrome users more choice over the search services they use.

Oil prices fell on Wednesday after U.S. President Donald Trump said U.S. and Iranian representatives held discussions at the United Nations.

TXNM Energy (NYSE:TXNM) declared a regular quarterly dividend of $0.4225 per share on its common stock following a board meeting held on September 22, 2026.

Royal Caribbean Group (NYSE:RCL) agreed to acquire a 50% equity interest in Sandals and Beaches Resorts for approximately $3 billion through a joint venture partnership.

Ionis Pharmaceuticals (NASDAQ:IONS) and Roche reported positive interim results from the Phase 3 IMAgINATION study of sefaxersen in adults with primary IgA nephropathy.

Shopify (NYSE:SHOP) shares rose after the company announced a partnership with Meta Platforms’ AI agent Muse to enable agentic checkout using Shop Pay across Shopify stores.

Filana Therapeutics (NASDAQ:FLNA) shares rose after the U.S. Food and Drug Administration lifted a clinical hold on its experimental drug simufilam for epilepsy linked to tuberous sclerosis complex.

Compass Therapeutics (NASDAQ:CMPX) shares declined after the U.S. Food and Drug Administration recommended an additional trial before the company submits a marketing application for tovecimig.

Amgen (NASDAQ:AMGN) said its experimental drug dazodalibep met the primary goal in a late-stage trial evaluating treatment for Sjogren’s disease.

Nutanix (NASDAQ:NTNX) acquired Ryax Technologies, a France-based AI-driven compute orchestration and management platform company, to expand its artificial intelligence infrastructure capabilities.

Oil prices declined to two-week lows on Tuesday as expectations for Gulf supply recovery improved following developments involving Iran and Saudi Arabia.

Endeavour Silver (NYSE:EXK) temporarily halted its primary ball mill at the Guanacevi Mine after identifying a mechanical issue on September 21, 2026.

Celldex Therapeutics (NASDAQ:CLDX) reported positive topline results from two Phase 3 trials evaluating barzolvolimab in adults with chronic spontaneous urticaria.